one-sided / two-sided [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2019-03-04 09:04 (880 d 17:35 ago) – Posting: # 19997
Views: 3,468

Hi Hötzi,


» In other words, if patients are treated with the originator’s product, there is a 5% risk that it does not perform better (more efficient and/or safer) than placebo.

There is no more than a 5% risk of approving the test product (=concluding superiority) if the test product is not superior.

» If we would test for BE at the 2.5% level (95% CI) we would be overly strict and at the same time gain absolutely nothing in terms of the patient’s risk.

The patient's risk would be halved (max 2.5% chance of approving a non-BE product; CIs would get wider).

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,596 posts in 4,516 threads, 1,532 registered users;
online 11 (0 registered, 11 guests [including 3 identified bots]).
Forum time: Sunday 03:39 CEST (Europe/Vienna)

Sit down before fact as a little child,
be prepared to give up every conceived notion,
follow humbly wherever and whatever abysses nature leads,
or you will learn nothing.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5